Colorectal Cancer Screening Gets a Refresh: What Doctors and Patients Need to Know
Starting March 15, 2026, a new framework will govern the supply of colorectal cancer screening kits in France. This change, implemented by the Assurance Maladie (the French national health insurance fund), impacts how physicians and pharmacists order and distribute these vital tests. The transition aims to streamline the organized colorectal cancer screening program and improve early detection rates.
What’s Changing with the Kits?
The core change revolves around a new contract for the kits themselves. Kits ordered on or after March 15, 2026, will be from the new contract. Kits ordered before this date, from the previous contract, can still be analyzed by laboratories, but only until September 15, 2026. After that date, only kits from the new contract will be accepted for analysis.
Healthcare professionals are advised against building up large stocks of the older kits. Patients who already have an older kit are encouraged to complete and return it promptly to ensure timely results.
How to Access Screening Kits
You’ll see now four ways individuals can obtain a colorectal cancer screening kit in France:
- Through their physician
- Through a pharmacy (pharmacists must have completed specific training)
- Through a state-qualified nurse
- Online via monkit.depistage-colorectal.fr (requiring FranceConnect authentication)
The kits utilize an immunological test to detect the presence of blood in stool samples.
Impact on Healthcare Professionals
For doctors and pharmacists, the primary change involves ordering through Amelipro. Orders placed after March 15, 2026, will automatically fulfill with the new kits. The Assurance Maladie emphasizes the importance of healthcare professionals actively offering kits to eligible patients – those aged 50 to 74 – to maximize participation in the screening program.
The laboratory Cerba is the designated processor for the samples, while a co-contractor of Cerba supplies the kits.
Why Early Detection Matters
Colorectal cancer is the third most common cancer in France, and the second leading cause of cancer-related deaths after lung cancer. However, the Assurance Maladie highlights that when diagnosed early, the prognosis is significantly improved, with a 90% survival rate.
Frequently Asked Questions
Q: What should I do if I already have an older kit?
A: Complete and return the kit as soon as possible, as it can only be analyzed until September 15, 2026.
Q: Who is eligible for colorectal cancer screening?
A: Men and women aged 50 to 74 are eligible.
Q: Is the screening test expensive?
A: No, the analysis of the test is fully covered by the Assurance Maladie.
Q: Can nurses now provide screening kits?
A: Yes, state-qualified nurses are now authorized to distribute the kits.
Did you know? Colorectal cancer is often preventable with regular screening and lifestyle modifications.
Pro Tip: Encourage your patients to discuss their screening options with you during routine check-ups.
Desire to learn more about cancer prevention and early detection? Explore our articles on lung cancer screening and breast cancer awareness.
Have questions or thoughts on the new screening process? Share your comments below!
